Sugi Predict

Sugi Predict / Compounds / SCHEMBL4081006

SCHEMBL4081006

SCHEMBL4081006

COc1ncnc2c1ncn2C1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 4/20 0.70
▸ ADORA1 P30542 2/20 0.69
▸ ADORA2A P29274 2/20 0.69
▸ ADORA2B P29275 2/20 0.69
▸ DPP4 P27487 1/20 0.69
▸ MEN1 O00255 1/20 0.69
▸ SLC28A1 O00337 1/20 0.69
▸ MAP3K7 O43318 1/20 0.69
▸ SLC28A2 O43868 1/20 0.69
▸ GAPDH P04406 1/20 0.69
▸ ADORA3 P0DMS8 1/20 0.69
▸ MAPK1 P28482 1/20 0.69
▸ STAT6 P42226 1/20 0.69
▸ PI4KA P42356 1/20 0.69
▸ KMT2A Q03164 1/20 0.69
▸ SMN1; SMN2 Q16637 1/20 0.69
▸ PI4K2B Q8TCG2 1/20 0.69
▸ DOT1L Q8TEK3 1/20 0.69
▸ PI4K2A Q9BTU6 1/20 0.69
▸ SLC28A3 Q9HAS3 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6903709 1.00 SLC29A1 (0.70) SLC29A1ADORA1ADORA2AADORA2BDPP4
SCHEMBL1979130 1.00 SLC29A1 (0.70) SLC29A1ADORA1ADORA2AADORA2BDPP4
SCHEMBL9142042 1.00 SLC29A1 (0.70) SLC29A1ADORA1ADORA2AADORA2BDPP4
SCHEMBL6887353 1.00 SLC29A1 (0.70) SLC29A1ADORA1ADORA2AADORA2BDPP4
SCHEMBL2589566 0.90 SLC29A1 (0.58) SLC29A1ADORA1ADORA2AADORA2BDPP4
SCHEMBL8970336 0.90 SLC29A1 (0.58) SLC29A1ADORA1ADORA2AADORA2BDPP4
SCHEMBL12552334 0.90 SLC29A1 (0.58) SLC29A1ADORA1ADORA2AADORA2BDPP4
SCHEMBL8970347 0.90 SLC29A1 (0.58) SLC29A1ADORA1ADORA2AADORA2BDPP4
SCHEMBL9141461 0.89 SLC29A1 (0.72) SLC29A1ADORA1ADORA2AADORA2BDPP4
SCHEMBL13265481 0.88 SLC29A1 (0.67) SLC29A1ADORA1ADORA2AADORA2BDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6355472-B2 ACID PHOSPHATASE AJINOMOTO CO., INC. (JP) 2002-03-12 — — US claimed
US-20020004590-A1 Method for producing nucleoside-5'-phosphate ester MIHARA YASUHIRO (JP) 2002-01-10 — — US claimed
US-6207435-B1 MUTANT ACID PHOSPHATASE HAVING DECREASED MICHAELIS CONSTANT FOR A NUCLEOSIDE AND/OR INCREASED TEMPERATURE STABILITY; FOR EFFICIENT PHOSPHORYLATION OF NUCLEOSIDES TO PRODUCE NUCLEOTIDES AJINOMOTO CO., INC. (JP) 2001-03-27 — — US claimed
US-6015697-A ECONOMICAL AND EFFICIENT PROCESS BY REACTING A NUCLEOSIDE WITH A PHOSPHATE DONOR GROUP IN PRESENCE OF MUTANT ACID PHOSPHATASE WITH DECREASED MICHAELIS CONSTANT FOR NUCLEOSIDE OR INCREASED TEMPERATURE STABILITY AJINOMOTO CO., INC. (JP) 2000-01-18 — — US claimed
US-5474929-A Adenosine deaminase gene NATIONAL RESEARCH COUNCIL OF CANADA (CA) 1995-12-12 — — US claimed
US-7575901-B2 Propagating escherichia mutant which produces 5'-inosinic acid or 5'-guanylic acid; identifying nucleotidase gene associated with generating nucleoside 5'-phosphate esters AJINOMOTO CO., INC. (JP) 2009-08-18 — — US disclosed
US-7345164-B2 Production method of 5′-acyloxynucleoside compound AJINOMOTO CO., INC. (JP) 2008-03-18 — — US disclosed
US-20080026428-A1 METHOD FOR PRODUCING NUCLEOTIDE BY FERMENTATION AJINOMOTO CO., INC. (JP) 2008-01-31 — — US disclosed
EP-0832970-B1 PROCESS FOR PRODUCING NUCLEOSIDE-5'-PHOSPHATE ESTER AJINOMOTO KK (JP) 2007-01-17 — — EP disclosed
EP-1170370-B1 Method for producing nucleotide by fermentation AJINOMOTO KK (JP) 2006-09-27 — — EP disclosed
US-20040230053-A1 Production method of 5'-acyloxynucleoside compound AJINOMOTO CO., INC. (JP) 2004-11-18 — — US disclosed
EP-1471071-A1 Production method of 5'-acyloxynucleoside compound Ajinmoto Co., Inc. (JP) 2004-10-27 — — EP disclosed
US-6010851-A ALLOWING AN ACID PHOSPHATASE HAVING A LOWERED PHOSPHOMONOESTERASE ACTIVITY TO ACT UNDER A CONDITION OF PH 3.0 TO 5.5 ON A NUCLEOSIDE AND A PHOSPHATE GROUP DONOR AJINOMOTO CO., INC. (JP) 2000-01-04 — — US disclosed
EP-0857788-A2 Method for producing nucleoside-5'-phosphate ester Ajinomoto Co., Inc. (JP) 1998-08-12 — — EP disclosed
US-5773424-A PARASITICIDE RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1998-06-30 — — US disclosed
EP-0832970-A1 PROCESS FOR PRODUCING NUCLEOSIDE-5'-PHOSPHATE Ajinomoto Co., Inc. (JP) 1998-04-01 — — EP disclosed
EP-0755255-A1 TREATMENT OF TOXOPLASMOSIS UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) 1997-01-29 — — EP disclosed
WO-1996018398-A1 TREATMENT OF TOXOPLASMOSIS THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) 1996-06-20 — — WO disclosed
US-5474929-A Adenosine deaminase gene NATIONAL RESEARCH COUNCIL OF CANADA (CA) 1995-12-12 — — US disclosed
US-5213972-A Production of thymidine and deoxyuridine, intermediates for AZT CHEMGEN CORPORATION (US) 1993-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040230053-A1 Production method of 5'-acyloxynucleoside compound ALKBH2, DUT, ALKBH1 SLC29A1 1450/4885ADORA1 1406/4885ADORA2A 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.